Skip to content

Ming T. Tsuang

7 papers in the library · 115 citations · publishing 2011-2026

Papers

Sort Most recent Most cited

Cannabis and tobacco co-use predicts psychosis in clinical high risk cohorts

Nature Mental Health May 1, 2026 Daniel Bello, Sophia H. Blyth, Rachel A Rabin et al.

Cannabis and tobacco use are highly prevalent among people with psychosis and are associated with medical comorbidities and poor prognosis. Concurrent use of cannabis and tobacco (‘co-use’) is rising in the general population, but has not been studied in psychosis. Given the devastating consequences of cannabis and tobacco use, it is critical to understand how their co-use affects psychiatric...

Cannabis and Tobacco Co-Use Is Associated With Impaired Neurocognitive Performance in Individuals at Clinical High Risk for Psychosis.

Biological Psychiatry: Cognitive Neuroscience and Neuroimaging April 1, 2026 Daniel Bello, J. Connolly, Jean Addington et al.

BACKGROUND Cannabis use is highly prevalent among people with psychotic disorders. While there is some indication that cannabis use exacerbates psychosis symptoms, its neurocognitive effects remain unclear. Co-use of cannabis and tobacco is increasing in the general population, but little is known about its effects in people with psychosis or those at risk for developing a psychotic disorder,...

Cannabis use and attenuated positive and negative symptoms in youth at clinical high risk for psychosis.

Schizophrenia Research August 25, 2022 Olga Santesteban-Echarri, Lu Liu, Madeline Miller et al.

Cannabis use is more prevalent among youth at clinical high-risk (CHR) for psychosis than healthy controls (HC). There is mixed evidence as to whether cannabis use is associated with increased severity of attenuated psychotic symptoms (APS) or whether current cannabis use is associated with the transition to psychosis. This study aims to assess cannabis use differences between CHR youth and HC...

Evaluating the relationship between cannabis use and IQ in youth and young adults at clinical high risk of psychosis

Psychiatry Research November 25, 2015 L. Buchy, L. Seidman, Kristin Cadenhead et al.

Among people with psychosis, those with a history of cannabis use show better cognitive performance than those who are cannabis naïve. It is unknown whether this pattern is present in youth at clinical high risk (CHR) of psychosis. We evaluated relationships between IQ and cannabis use while controlling for use of other substances known to impact cognition in 678 CHR and 263 healthy control...

Alcohol confounds relationship between cannabis misuse and psychosis conversion in a high‐risk sample

Acta Psychiatrica Scandinavica January 9, 2015 Andrea M. Auther, Kristin Cadenhead, Ricardo E Carrión et al. 46 citations

OBJECTIVE: Cannabis use has been examined as a predictor of psychosis in clinical high-risk (CHR) samples, but little is known about the impact of other substances on this relationship. METHOD: Substance use was assessed in a large sample of CHR participants (N = 370, mean age = 18.3) enrolled in the multisite North American Prodrome Longitudinal Study Phase 1 project. Three hundred and...

Cannabis use and cognitive dysfunction

Indian Journal of Psychiatry 2011 Amresh Shrivastava, Megan Johnston, Ming T. Tsuang 69 citations

This review considers the effects of cannabis on cognitive functioning, in both short and long term. Although the general impression supported by many studies is that cannabis causes cognitive decline, particularly with long-term usage, some research suggests that this may not be the case. Nevertheless, certain specific neuropsychological parameters have been found to be affected. Most commonly...

Longitudinal Relationships Between Cannabis and Tobacco Use and Symptom Severity in Individuals at Clinical High Risk for Psychosis

Yunong Bai, Simon N. Vandekar, Brandee Feola et al.

Abstract Objective Tobacco and cannabis are the most used substances among individuals at clinical high risk for psychosis (CHR-P), but it remains controversial whether substance use drives symptom exacerbation and psychosis transition, or vice versa. We investigated longitudinal dose-response relationships of tobacco and cannabis use with clinical presentation in a CHR-P population. Methods...